vs
Side-by-side financial comparison of AlTi Global, Inc. (ALTI) and NATURES SUNSHINE PRODUCTS INC (NATR). Click either name above to swap in a different company.
NATURES SUNSHINE PRODUCTS INC is the larger business by last-quarter revenue ($123.8M vs $86.6M, roughly 1.4× AlTi Global, Inc.). NATURES SUNSHINE PRODUCTS INC runs the higher net margin — 3.3% vs -15.1%, a 18.5% gap on every dollar of revenue. On growth, AlTi Global, Inc. posted the faster year-over-year revenue change (87.0% vs 4.7%). NATURES SUNSHINE PRODUCTS INC produced more free cash flow last quarter ($7.6M vs $-52.2M). Over the past eight quarters, AlTi Global, Inc.'s revenue compounded faster (30.6% CAGR vs 5.6%).
Cristal Global is the world's second-largest producer of titanium dioxide and a leading producer of titanium chemicals. It was formed when The National Titanium Dioxide Company Ltd. combined with Millennium Chemicals. The headquarters are in Jeddah, Saudi Arabia. It is a significant shareholder in Bemax, the world’s 5th largest TiO2 feedstock producer.
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
ALTI vs NATR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.6M | $123.8M |
| Net Profit | $-13.1M | $4.1M |
| Gross Margin | — | 72.5% |
| Operating Margin | -2.1% | 4.3% |
| Net Margin | -15.1% | 3.3% |
| Revenue YoY | 87.0% | 4.7% |
| Net Profit YoY | 75.6% | 1379.4% |
| EPS (diluted) | — | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.6M | $123.8M | ||
| Q3 25 | $57.2M | $128.3M | ||
| Q2 25 | $53.1M | $114.8M | ||
| Q1 25 | $58.0M | $113.2M | ||
| Q4 24 | $46.3M | $118.2M | ||
| Q3 24 | $51.8M | $114.6M | ||
| Q2 24 | $49.5M | $110.6M | ||
| Q1 24 | $50.8M | $111.0M |
| Q4 25 | $-13.1M | $4.1M | ||
| Q3 25 | $-84.1M | $5.3M | ||
| Q2 25 | $-24.4M | $5.3M | ||
| Q1 25 | $1.9M | $4.7M | ||
| Q4 24 | $-53.8M | $-321.0K | ||
| Q3 24 | $-72.5M | $4.3M | ||
| Q2 24 | $-6.4M | $1.3M | ||
| Q1 24 | $29.7M | $2.3M |
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 73.3% | ||
| Q2 25 | — | 71.7% | ||
| Q1 25 | — | 72.1% | ||
| Q4 24 | — | 72.0% | ||
| Q3 24 | — | 71.3% | ||
| Q2 24 | — | 71.4% | ||
| Q1 24 | — | 71.2% |
| Q4 25 | -2.1% | 4.3% | ||
| Q3 25 | -49.8% | 7.0% | ||
| Q2 25 | -56.7% | 3.7% | ||
| Q1 25 | -23.3% | 5.4% | ||
| Q4 24 | -42.7% | 3.8% | ||
| Q3 24 | -18.4% | 4.6% | ||
| Q2 24 | -30.2% | 5.1% | ||
| Q1 24 | -28.9% | 4.2% |
| Q4 25 | -15.1% | 3.3% | ||
| Q3 25 | -147.0% | 4.2% | ||
| Q2 25 | -45.9% | 4.6% | ||
| Q1 25 | 3.3% | 4.2% | ||
| Q4 24 | -116.1% | -0.3% | ||
| Q3 24 | -140.0% | 3.8% | ||
| Q2 24 | -12.9% | 1.2% | ||
| Q1 24 | 58.4% | 2.1% |
| Q4 25 | — | $0.23 | ||
| Q3 25 | — | $0.30 | ||
| Q2 25 | $-0.33 | $0.28 | ||
| Q1 25 | $-0.04 | $0.25 | ||
| Q4 24 | $-0.71 | $-0.02 | ||
| Q3 24 | $-0.88 | $0.23 | ||
| Q2 24 | $-0.18 | $0.07 | ||
| Q1 24 | $0.18 | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $41.2M | $93.9M |
| Total DebtLower is stronger | $883.0K | — |
| Stockholders' EquityBook value | $600.1M | $161.6M |
| Total Assets | $1.2B | $261.1M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $41.2M | $93.9M | ||
| Q3 25 | $35.8M | $95.6M | ||
| Q2 25 | $42.4M | $81.3M | ||
| Q1 25 | $52.8M | $86.5M | ||
| Q4 24 | $64.4M | $84.7M | ||
| Q3 24 | $220.6M | $78.7M | ||
| Q2 24 | $60.0M | $68.7M | ||
| Q1 24 | $134.2M | $77.8M |
| Q4 25 | $883.0K | — | ||
| Q3 25 | $586.0K | — | ||
| Q2 25 | $673.0K | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $128.4M | — | ||
| Q2 24 | $164.0M | — | ||
| Q1 24 | $183.7M | $2.1M |
| Q4 25 | $600.1M | $161.6M | ||
| Q3 25 | $607.2M | $166.7M | ||
| Q2 25 | $685.4M | $163.7M | ||
| Q1 25 | $665.2M | $167.1M | ||
| Q4 24 | $658.4M | $161.0M | ||
| Q3 24 | $707.0M | $162.6M | ||
| Q2 24 | $540.2M | $156.4M | ||
| Q1 24 | $510.9M | $159.7M |
| Q4 25 | $1.2B | $261.1M | ||
| Q3 25 | $1.2B | $264.8M | ||
| Q2 25 | $1.2B | $254.9M | ||
| Q1 25 | $1.2B | $252.7M | ||
| Q4 24 | $1.3B | $240.9M | ||
| Q3 24 | $1.4B | $245.3M | ||
| Q2 24 | $1.3B | $235.8M | ||
| Q1 24 | $1.3B | $247.3M |
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.18× | — | ||
| Q2 24 | 0.30× | — | ||
| Q1 24 | 0.36× | 0.01× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-51.4M | $9.9M |
| Free Cash FlowOCF − Capex | $-52.2M | $7.6M |
| FCF MarginFCF / Revenue | -60.3% | 6.1% |
| Capex IntensityCapex / Revenue | 0.9% | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.41× |
| TTM Free Cash FlowTrailing 4 quarters | — | $28.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-51.4M | $9.9M | ||
| Q3 25 | $-53.5M | $18.5M | ||
| Q2 25 | $-19.9M | $4.3M | ||
| Q1 25 | $-30.2M | $2.6M | ||
| Q4 24 | $-50.7M | $12.2M | ||
| Q3 24 | $-4.9M | $9.6M | ||
| Q2 24 | $-30.2M | $1.3M | ||
| Q1 24 | $-15.5M | $2.2M |
| Q4 25 | $-52.2M | $7.6M | ||
| Q3 25 | — | $16.8M | ||
| Q2 25 | $-20.0M | $3.0M | ||
| Q1 25 | $-31.0M | $1.5M | ||
| Q4 24 | $-58.2M | $10.0M | ||
| Q3 24 | $-9.4M | $7.9M | ||
| Q2 24 | $-31.2M | $-2.0M | ||
| Q1 24 | $-15.7M | $-1.5M |
| Q4 25 | -60.3% | 6.1% | ||
| Q3 25 | — | 13.1% | ||
| Q2 25 | -37.6% | 2.6% | ||
| Q1 25 | -53.4% | 1.3% | ||
| Q4 24 | -125.7% | 8.5% | ||
| Q3 24 | -18.2% | 6.9% | ||
| Q2 24 | -63.2% | -1.9% | ||
| Q1 24 | -30.9% | -1.4% |
| Q4 25 | 0.9% | 1.9% | ||
| Q3 25 | 0.0% | 1.3% | ||
| Q2 25 | 0.0% | 1.2% | ||
| Q1 25 | 1.3% | 1.0% | ||
| Q4 24 | 16.3% | 1.9% | ||
| Q3 24 | 8.7% | 1.5% | ||
| Q2 24 | 2.2% | 3.0% | ||
| Q1 24 | 0.4% | 3.3% |
| Q4 25 | — | 2.41× | ||
| Q3 25 | — | 3.46× | ||
| Q2 25 | — | 0.81× | ||
| Q1 25 | -15.80× | 0.55× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.21× | ||
| Q2 24 | — | 0.97× | ||
| Q1 24 | -0.52× | 0.94× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALTI
| Management Advisory Fees | $51.1M | 59% |
| Other | $32.7M | 38% |
| Distributions From Investments | $2.9M | 3% |
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
